Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Return on Equity (2024 - 2025)

Prelude Therapeutics' Return on Equity history spans 2 years, with the latest figure at 1.64% for Q4 2025.

  • For Q4 2025, Return on Equity fell 67.0% year-over-year to 1.64%; the TTM value through Dec 2025 reached 1.64%, down 67.0%, while the annual FY2025 figure was 1.05%, N/A changed from the prior year.
  • Return on Equity for Q4 2025 was 1.64% at Prelude Therapeutics, up from 1.8% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.97% in Q4 2024 and bottomed at 1.8% in Q3 2025.